Скачать или смотреть Live Webinar Monitoring Solid Organ Transplant Health with Donor derived Cell free DNA 2

Cell-free DNA (cfDNA) has emerged as a powerful biomarker for monitoring allograft health and detecting rejection in solid organ transplantation. Since 2022, the Paris Transplant Group-PITOR has implemented a dedicated cfDNA platform, integrating this innovative approach into routine clinical practice.

This initiative has enabled large-scale monitoring across multiple transplant centers, with a steady growth in sample volume and clinical adoption. Through real-world data, we demonstrate how cfDNA improves patient follow-up, supports earlier rejection detection, and facilitates the development of new clinical protocols. This webinar will provide an overview of the platform’s trajectory, highlight key milestones, and discuss the integration of cfDNA into both clinical care and research.

Learning Objectives
Utility of cell-free DNA (cfDNA) as an advanced biomarker for assessing allograft health and detecting rejection in solid organ transplant patients
Practical implementation and integration of a dedicated cell-free DNA (cfDNA) platform into routine clinical practice, drawing insights from initiatives like the Paris Transplant Group-PITOR
Key clinical benefits and real-world impact of cfDNA monitoring, including improved patient follow-up, earlier rejection detection, and the development of new clinical protocols